Jim Simons’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.12M Buy
643,777
+90,613
+16% +$149K ﹤0.01% 2212
2025
Q4
$963K Sell
553,164
-263,175
-32% -$580K ﹤0.01% 2304
2025
Q3
$1.91M Buy
816,339
+488,210
+149% +$935K ﹤0.01% 2111
2025
Q2
$668K Buy
328,129
+282,301
+616% +$541K ﹤0.01% 2692
2025
Q1
$74.7K Sell
45,828
-196,477
-81% -$394K ﹤0.01% 3234
2024
Q4
$443K Sell
242,305
-88,761
-27% -$393K ﹤0.01% 2898
2024
Q3
$1.91M Sell
331,066
-79,500
-19% -$656K ﹤0.01% 2052
2024
Q2
$3.32M Sell
410,566
-39,700
-9% -$418K 0.01% 1562
2024
Q1
$6.25M Sell
450,266
-157,849
-26% -$1.36M 0.01% 1269
2023
Q4
$3.72M Buy
608,115
+200,657
+49% +$990K 0.01% 1542
2023
Q3
$1.9M Sell
407,458
-45,565
-10% -$252K ﹤0.01% 1898
2023
Q2
$2.43M Buy
453,023
+232,998
+106% +$1.88M ﹤0.01% 1864
2023
Q1
$2.17M Buy
220,025
+5,650
+3% +$96.3K ﹤0.01% 1983
2022
Q4
$4.01M Buy
214,375
+20,733
+11% +$470K 0.01% 1650
2022
Q3
$4.01M Buy
193,642
+62,184
+47% +$1.59M 0.01% 1575
2022
Q2
$2.73M Buy
131,458
+98,635
+301% +$2.78M ﹤0.01% 1970
2022
Q1
$1.41M Buy
+32,823
New +$1.48M ﹤0.01% 2486
2020
Q2
Sell
-50,260
Closed -$4.49M 3591
2020
Q1
$4.49M Buy
50,260
+20,302
+68% +$1.25M ﹤0.01% 1632
2019
Q4
$1.19M Buy
29,958
+18,716
+166% +$563K ﹤0.01% 2551
2019
Q3
$277K Sell
11,242
-6,648
-37% -$202K ﹤0.01% 3059
2019
Q2
$631K Sell
17,890
-29,133
-62% -$1.16M ﹤0.01% 2905
2019
Q1
$2.1M Buy
47,023
+19,083
+68% +$962K ﹤0.01% 2284
2018
Q4
$1.34M Sell
27,940
-3,342
-11% -$203K ﹤0.01% 2440
2018
Q3
$2.09M Buy
31,282
+5,309
+20% +$296K ﹤0.01% 2249
2018
Q2
$1.22M Sell
25,973
-3,175
-11% -$175K ﹤0.01% 2517
2018
Q1
$1.65M Sell
29,148
-1,184
-4% -$64.1K ﹤0.01% 2434
2017
Q4
$1.5M Buy
+30,332
New +$1.88M ﹤0.01% 2489
2016
Q1
Sell
-32,732
Closed -$2.64M 3436
2015
Q4
$2.64M Buy
+32,732
New +$2.61M 0.01% 1931

Other funds holding INO

Jim Simons's INO Position: Q1 2026 in Review

Jim Simons increased its Inovio Pharmaceuticals (INO) stake by 16% in Q1 2026, buying an estimated $149K and bringing the position to 643,777 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Jim Simons first reported a position in INO in Q4 2015 and has held it in 28 quarters since. The position peaked at $6.25M in Q1 2024. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Jim Simons held 643,777 shares of Inovio Pharmaceuticals worth $1.12M as of Q1 2026.
  • Jim Simons bought 90,613 Inovio Pharmaceuticals shares in Q1 2026, an estimated $149K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2212 holding.
  • Jim Simons first reported a position in Inovio Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • Jim Simons's Inovio Pharmaceuticals position peaked at $6.25M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.